Back to Directory
ArkVax
Founded 2020
Glycoconjugate vaccines for livestock
ArkVax is a veterinary biotechnology company developing glycoconjugate vaccines against bacterial diseases in livestock. Its research draws on glycoengineering technology developed at the London School of Hygiene & Tropical Medicine. The company aims to make this class of vaccine affordable for animal health applications. Preventing bacterial disease in livestock could reduce the need for antibiotics, a stated objective of its vaccine development programme.